A Phase 1 / 2a Study of In-situ REIC/Dkk-3 Therapy in Subjects With Localized Prostate Cancer.

Trial Profile

A Phase 1 / 2a Study of In-situ REIC/Dkk-3 Therapy in Subjects With Localized Prostate Cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Ad5 SGE DKK3 gene therapy-Momotaro (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Momotaro-Gene
  • Most Recent Events

    • 29 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 29 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 05 Oct 2014 Planned End Date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top